Feedback / Questions
dimethylamino micheliolide (ACT001) - Tianjin Suntech Pharma
https://www.businesswire.com/news/home/20250929912412/en/Accendatechs-Phase-3-Trial-of-ACT001-an-Oral-Compound-with-Novel-MoA-Begins-Enrolling-Patients-with-Small-Cell-Lung-Cancer-with-Brain-Metastasis-in-a-Highly-Competitive-Research-Field
Sep 29, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next